Monthly Archives: February 2014

March 28 – Tomorrow’s Rules of the Game with Mathieu Trépanier Geneva Chapter

Date
Posted by
Comments0

Normal
0

false
false
false

FR
JA
X-NONE

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:”Times New Roman”,”serif”;
mso-ansi-language:FR;}
[notice]NEW Date is March 28[/notice]

“Competing for Tomorrow’s Rules of the Game”, by Mathieu Trépanier, Managing Director Tsquared Consulting & Partners – Geneva Event on March 28th. More Details and Tickets available on http://de.amiando.com/newrulesofthegame14.html

 

March 12, 2014 BioMed Up Investment in Life Science Startups

Date
Posted by
March 12, 2014 BioMed Up Investment in Life Science Startups

v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}

BioMed Up:

Investment in Life Science Start-ups

Geneva Biotech Campus, Geneva, March 12 2014, starting at 18.00

The INSEAD Swiss Healthcare Industry Club (cHIC) is extending partnerships with the EPFL A3 Angels, the Business Angels and the Mentoring Club of EPFL alumni. The Geneva Biotech Campus is located in the former Merck Serono building in Geneva.

[important]Tickets on Xing http://de.amiando.com/BiomedUp.html[/important]

Conference theme, speakers and debate approach

How can Angel investors support life science start-ups with capital, expertise?  Switzerland is a hot-bed for the development of life sciences technologies and ranked first in the INSEAD Global Innovation Index 2012. However, the financing opportunities for life science startups have eroded, as described in Ernst & Young’s “Pulse of the industry report” 2013. Venture capital investment was down 21% in 2012-13 to its lowest level in more than a decade. The Swiss Commission for Technology and Innovation, SECA and CTI-Invest are encouraging private investment from Business Angels to fill the gap. We will address these opportunities and challenges with an outstanding panel of experts and in presence of several Swiss start-up companies:

Key trends in medtech and biotech investments seen by experts including:

  • Angelo De Rosa, Director, Strategy & Business Development at Medtronic
  • David Deperthes, Vice President Business Development Debiopharm
  • Benoît Dubuis, Director Wyss Center for Bio and Neuroengineering
  • Frank Kumli, Ernst & Young Healthcare practice

Ask your questions to a panel featuring highly successful entrepreneurs: 

  • Nicolas Durand, Founder at Abionic,
  • Vital Verin, founder Endosense and Mestro-Heart,
  • Jean-Pierre Rosat, CEO at Aleva Neurotherapeutics,
  • Jean-Marc Wismer, CEO Sensimed.
  • Moderated by Nafida Bendali, Investor relations consultant in life sciences

The attendance fee is CHF 75 per person. [notice]The seating is limited![/notice]

trailerbiomedup